Directly Reprogrammed NK Cells Driven by BCL11B Depletion Enhance Targeted Immunotherapy Against Pancreatic Ductal Adenocarcinoma

Directly Reprogrammed NK Cells Driven by BCL11B Depletion Enhance Targeted Immunotherapy against Pancreatic Ductal Adenocarcinoma

Scientists presented a synergistic immunotherapy platform that integrates natural killer reprogramming, CAR engineering, and tumor sensitization. The combinatorial approach significantly enhances antitumor efficacy in PDAC and offers a promising strategy for overcoming immune resistance in solid tumors. [Journal of Hematology & Oncology] Full Article

Tandem CAR T cells targeting mesothelin and MUC16 overcome tumor heterogeneity by targeting one antigen at a time

Researchers have demonstrated that a tandem CAR T cell targeting mesothelin and MUC16 ectodomain is able to outmaneuver tumor heterogeneity, outperforming single target CAR T cells in mixed ovarian and pancreatic models.